Adam S. Feldman, MD, MPH, is a urologist at the Massachusetts General Hospital Department of Urology. He specializes in the treatment of cancer and related research.
Dr. Adam Feldman is a faculty member of the Department of Urology and a Urologic Oncologist at Massachusetts General Hospital. Dr. Feldman completed his residency in urology in 2006 and subsequently completed his fellowship in urologic oncology in June 2008. His clinical practice is focused on the surgical management of genitourinary cancer using both open and laparoscopic techniques. Dr. Feldman also is involved in clinical and translational research in cancers of the prostate, bladder, kidney and penis. He recently received a three year Young Investigator Award from the Prostate Cancer Foundation for his work in biomarker discovery and analysis in prostate cancer.
Feldman AS, Banyard J, Wu C-L, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009;15(3):1024-31.
Kaufman DS, Shipley WU, Feldman AS. Bladder Cancer. The Lancet. 2009; 374(9685):239-49.
Feldman AS and Dahl DM. , 2006. June, 2-6, 2006. Laparoscopic Radical Prostatectomy. US Oncological Disease 2006. 2006: pp. 56-58.
Feldman AS, McDougal WS, Harisinghani MG. The potential of nanoparticle-enhanced imaging. The Journal of Urologic Oncology, Seminar Section. 2008;26(1):65-73.
Feldman AS, Daha AK, Osbourne AL, et al. Case-matched analysis of radiofrequency ablation vs. open and laparoscopic partial nephrectomy: What is the effect on GFR? Accepted for presentation at the ASCO GU Cancer Symposium, 2010.
MGH Hotline 02.04.11 To promote awareness about the disease and the importance of self-exams, the MGH and CBS Cares are collaborating on a fun, informative public service announcement (PSA).